Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Recombinant cholera toxin B subunit (rCTB) which is produced by Bacillus brevis carrying pNU212-CTB acts as a mucosal adjuvant capable of enhancing host immune responses specific to unrelated, mucosally co-administered vaccine antigens. When mice were administered intranasally with diphtheria-pertussis-tetanus (DPT) combination vaccine consisting of diphtheria toxoid (DTd), tetanus toxoid (TTd), pertussis toxoid (PTd), and formalin-treated filamentous hemagglutinin (fFHA), the presence of rCTB elevated constantly high values of DTd- and TTd-specific serum ELISA IgG antibody titres, and protective levels of diphtheria and tetanus toxin-neutralizing antibodies but the absence of rCTB did not. Moreover, the addition of rCTB protected all mice against tetanic symptoms and deaths. DPT combination vaccine raised high levels of serum anti-PT IgG antibody titres regardless of rCTB and protected mice from Bordetella pertussis challenge. These results suggest that co-administration of rCTB as an adjuvant is necessary for induction of diphtheria and tetanus antitoxin antibodies on the occasion of intranasal administration of DPT combination vaccine.
Isaka
Masanori
M
Department of Microbiology, Nagoya City University, Medical School, Mizuho-ku, Nagoya 467-8601, Japan.
Komiya
Takako
T
Takahashi
Motohide
M
Yasuda
Yoko
Y
Taniguchi
Tooru
T
Zhao
Yanqiu
Y
Matano
Keiko
K
Matsui
Hideyuki
H
Maeyama
Jun-Ichi
J
Morokuma
Kazunori
K
Ohkuma
Kunio
K
Goto
Norihisa
N
Tochikubo
Kunio
K
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000281:Administration, Intranasal; D000372:Agglutination Tests; D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology; D002138:Calibration; D002478:Cells, Cultured; D002772:Cholera Toxin / Q000494:pharmacology*; D004166:Diphtheria Antitoxin / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005557:Formaldehyde; D006388:Hemagglutinins / Q000276:immunology; D018928:Immunity, Mucosal / Q000187:drug effects / Q000276:immunology*; D007070:Immunoglobulin A / Q000032:analysis / Q000096:biosynthesis; D007073:Immunoglobulin E / Q000032:analysis / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology; D013743:Tetanus Antitoxin / Q000276:immunology*
D000276:Adjuvants, Immunologic; D004166:Diphtheria Antitoxin; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D013743:Tetanus Antitoxin; D005557:Formaldehyde; D007073:Immunoglobulin E; D002772:Cholera Toxin